Simultaneous Evaluation of Safety, Acceptability, Pericoital Kinetics, and Ex Vivo Pharmacodynamics Comparing Four Rectal Microbicide Vehicle Candidates

Francisco Leyva, Edward J. Fuchs, Rahul Bakshi, Alex Carballo-Dieguez, Ana Ventuneac, Chen Yue, Brian Caffo, Yong Du, Michael Torbenson, Liye Li, Gerald Mullin, Linda Lee, Lisa Rohan, Peter A. Anton, Craig W. Hendrix

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Preexposure prophylaxis (PrEP) of HIV infection with tenofovir-containing regimens is effective, but plagued by poor adherence in some studies. Options for safe, effective, and acceptable PrEP products, especially for men and women at risk of HIV via receptive anal intercourse (RAI), are needed. We performed a randomized, partially blinded, first-in-human evaluation of four candidate rectal microbicide vehicles - aqueous gel, aqueous fluid, lipid gel, and lipid fluid - to select a prototype for further clinical development. Eight seronegative participants received three doses of each product with each dose separated by at least 2 weeks: one dose was given alone without simulated RAI in clinic, another dose was followed by simulated RAI in clinic, and another dose was self-administered at home in the context of RAI with a partner. Assessments included safety, acceptability, colon histology, ex vivo HIV infectivity of colon tissue explants, and colonic luminal distribution of vehicle and HIV surrogates. Adverse events were all mild and mainly sigmoidoscopy associated. There were minor differences in colon distribution of products and little effect of RAI. Vehicle distribution covered 95% (±7% standard deviation) of the distribution of an HIV surrogate in the colonic lumen. The lipid fluid vehicle increased HIV colon tissue infectability 5-fold [log10 p24 0.68 (95% confidence interval 0.08, 1.28)] and aqueous gel provided 6-fold protection [log10 p24 0.80 (95% confidence interval 0.20, 1.41)] compared to no product baseline. Colon permeability of lipid vehicles was more than 10-fold greater than aqueous vehicles. All products received similar acceptability ratings, though trends favored the gel products. Intensive simultaneous assessment of safety and toxicity, luminal and tissue distribution, ex vivo HIV infectivity, and product acceptability in relevant sexual contexts provided clear differentiation among candidate gels very early in product development. We selected the aqueous gel for further development as a rectal microbicide vehicle.

Original languageEnglish (US)
Pages (from-to)1089-1097
Number of pages9
JournalAIDS Research and Human Retroviruses
Volume31
Issue number11
DOIs
StatePublished - Nov 1 2015

Fingerprint

Anti-Infective Agents
Gels
HIV
Colon
Safety
Lipids
Tenofovir
Confidence Intervals
Sigmoidoscopy
Tissue Distribution
HIV Infections
Permeability
Histology

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Infectious Diseases

Cite this

Simultaneous Evaluation of Safety, Acceptability, Pericoital Kinetics, and Ex Vivo Pharmacodynamics Comparing Four Rectal Microbicide Vehicle Candidates. / Leyva, Francisco; Fuchs, Edward J.; Bakshi, Rahul; Carballo-Dieguez, Alex; Ventuneac, Ana; Yue, Chen; Caffo, Brian; Du, Yong; Torbenson, Michael; Li, Liye; Mullin, Gerald; Lee, Linda; Rohan, Lisa; Anton, Peter A.; Hendrix, Craig W.

In: AIDS Research and Human Retroviruses, Vol. 31, No. 11, 01.11.2015, p. 1089-1097.

Research output: Contribution to journalArticle

Leyva, F, Fuchs, EJ, Bakshi, R, Carballo-Dieguez, A, Ventuneac, A, Yue, C, Caffo, B, Du, Y, Torbenson, M, Li, L, Mullin, G, Lee, L, Rohan, L, Anton, PA & Hendrix, CW 2015, 'Simultaneous Evaluation of Safety, Acceptability, Pericoital Kinetics, and Ex Vivo Pharmacodynamics Comparing Four Rectal Microbicide Vehicle Candidates', AIDS Research and Human Retroviruses, vol. 31, no. 11, pp. 1089-1097. https://doi.org/10.1089/aid.2015.0086
Leyva, Francisco ; Fuchs, Edward J. ; Bakshi, Rahul ; Carballo-Dieguez, Alex ; Ventuneac, Ana ; Yue, Chen ; Caffo, Brian ; Du, Yong ; Torbenson, Michael ; Li, Liye ; Mullin, Gerald ; Lee, Linda ; Rohan, Lisa ; Anton, Peter A. ; Hendrix, Craig W. / Simultaneous Evaluation of Safety, Acceptability, Pericoital Kinetics, and Ex Vivo Pharmacodynamics Comparing Four Rectal Microbicide Vehicle Candidates. In: AIDS Research and Human Retroviruses. 2015 ; Vol. 31, No. 11. pp. 1089-1097.
@article{190162cff2ef423abf60e3c32812f7d6,
title = "Simultaneous Evaluation of Safety, Acceptability, Pericoital Kinetics, and Ex Vivo Pharmacodynamics Comparing Four Rectal Microbicide Vehicle Candidates",
abstract = "Preexposure prophylaxis (PrEP) of HIV infection with tenofovir-containing regimens is effective, but plagued by poor adherence in some studies. Options for safe, effective, and acceptable PrEP products, especially for men and women at risk of HIV via receptive anal intercourse (RAI), are needed. We performed a randomized, partially blinded, first-in-human evaluation of four candidate rectal microbicide vehicles - aqueous gel, aqueous fluid, lipid gel, and lipid fluid - to select a prototype for further clinical development. Eight seronegative participants received three doses of each product with each dose separated by at least 2 weeks: one dose was given alone without simulated RAI in clinic, another dose was followed by simulated RAI in clinic, and another dose was self-administered at home in the context of RAI with a partner. Assessments included safety, acceptability, colon histology, ex vivo HIV infectivity of colon tissue explants, and colonic luminal distribution of vehicle and HIV surrogates. Adverse events were all mild and mainly sigmoidoscopy associated. There were minor differences in colon distribution of products and little effect of RAI. Vehicle distribution covered 95{\%} (±7{\%} standard deviation) of the distribution of an HIV surrogate in the colonic lumen. The lipid fluid vehicle increased HIV colon tissue infectability 5-fold [log10 p24 0.68 (95{\%} confidence interval 0.08, 1.28)] and aqueous gel provided 6-fold protection [log10 p24 0.80 (95{\%} confidence interval 0.20, 1.41)] compared to no product baseline. Colon permeability of lipid vehicles was more than 10-fold greater than aqueous vehicles. All products received similar acceptability ratings, though trends favored the gel products. Intensive simultaneous assessment of safety and toxicity, luminal and tissue distribution, ex vivo HIV infectivity, and product acceptability in relevant sexual contexts provided clear differentiation among candidate gels very early in product development. We selected the aqueous gel for further development as a rectal microbicide vehicle.",
author = "Francisco Leyva and Fuchs, {Edward J.} and Rahul Bakshi and Alex Carballo-Dieguez and Ana Ventuneac and Chen Yue and Brian Caffo and Yong Du and Michael Torbenson and Liye Li and Gerald Mullin and Linda Lee and Lisa Rohan and Anton, {Peter A.} and Hendrix, {Craig W.}",
year = "2015",
month = "11",
day = "1",
doi = "10.1089/aid.2015.0086",
language = "English (US)",
volume = "31",
pages = "1089--1097",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "11",

}

TY - JOUR

T1 - Simultaneous Evaluation of Safety, Acceptability, Pericoital Kinetics, and Ex Vivo Pharmacodynamics Comparing Four Rectal Microbicide Vehicle Candidates

AU - Leyva, Francisco

AU - Fuchs, Edward J.

AU - Bakshi, Rahul

AU - Carballo-Dieguez, Alex

AU - Ventuneac, Ana

AU - Yue, Chen

AU - Caffo, Brian

AU - Du, Yong

AU - Torbenson, Michael

AU - Li, Liye

AU - Mullin, Gerald

AU - Lee, Linda

AU - Rohan, Lisa

AU - Anton, Peter A.

AU - Hendrix, Craig W.

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Preexposure prophylaxis (PrEP) of HIV infection with tenofovir-containing regimens is effective, but plagued by poor adherence in some studies. Options for safe, effective, and acceptable PrEP products, especially for men and women at risk of HIV via receptive anal intercourse (RAI), are needed. We performed a randomized, partially blinded, first-in-human evaluation of four candidate rectal microbicide vehicles - aqueous gel, aqueous fluid, lipid gel, and lipid fluid - to select a prototype for further clinical development. Eight seronegative participants received three doses of each product with each dose separated by at least 2 weeks: one dose was given alone without simulated RAI in clinic, another dose was followed by simulated RAI in clinic, and another dose was self-administered at home in the context of RAI with a partner. Assessments included safety, acceptability, colon histology, ex vivo HIV infectivity of colon tissue explants, and colonic luminal distribution of vehicle and HIV surrogates. Adverse events were all mild and mainly sigmoidoscopy associated. There were minor differences in colon distribution of products and little effect of RAI. Vehicle distribution covered 95% (±7% standard deviation) of the distribution of an HIV surrogate in the colonic lumen. The lipid fluid vehicle increased HIV colon tissue infectability 5-fold [log10 p24 0.68 (95% confidence interval 0.08, 1.28)] and aqueous gel provided 6-fold protection [log10 p24 0.80 (95% confidence interval 0.20, 1.41)] compared to no product baseline. Colon permeability of lipid vehicles was more than 10-fold greater than aqueous vehicles. All products received similar acceptability ratings, though trends favored the gel products. Intensive simultaneous assessment of safety and toxicity, luminal and tissue distribution, ex vivo HIV infectivity, and product acceptability in relevant sexual contexts provided clear differentiation among candidate gels very early in product development. We selected the aqueous gel for further development as a rectal microbicide vehicle.

AB - Preexposure prophylaxis (PrEP) of HIV infection with tenofovir-containing regimens is effective, but plagued by poor adherence in some studies. Options for safe, effective, and acceptable PrEP products, especially for men and women at risk of HIV via receptive anal intercourse (RAI), are needed. We performed a randomized, partially blinded, first-in-human evaluation of four candidate rectal microbicide vehicles - aqueous gel, aqueous fluid, lipid gel, and lipid fluid - to select a prototype for further clinical development. Eight seronegative participants received three doses of each product with each dose separated by at least 2 weeks: one dose was given alone without simulated RAI in clinic, another dose was followed by simulated RAI in clinic, and another dose was self-administered at home in the context of RAI with a partner. Assessments included safety, acceptability, colon histology, ex vivo HIV infectivity of colon tissue explants, and colonic luminal distribution of vehicle and HIV surrogates. Adverse events were all mild and mainly sigmoidoscopy associated. There were minor differences in colon distribution of products and little effect of RAI. Vehicle distribution covered 95% (±7% standard deviation) of the distribution of an HIV surrogate in the colonic lumen. The lipid fluid vehicle increased HIV colon tissue infectability 5-fold [log10 p24 0.68 (95% confidence interval 0.08, 1.28)] and aqueous gel provided 6-fold protection [log10 p24 0.80 (95% confidence interval 0.20, 1.41)] compared to no product baseline. Colon permeability of lipid vehicles was more than 10-fold greater than aqueous vehicles. All products received similar acceptability ratings, though trends favored the gel products. Intensive simultaneous assessment of safety and toxicity, luminal and tissue distribution, ex vivo HIV infectivity, and product acceptability in relevant sexual contexts provided clear differentiation among candidate gels very early in product development. We selected the aqueous gel for further development as a rectal microbicide vehicle.

UR - http://www.scopus.com/inward/record.url?scp=84946709487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946709487&partnerID=8YFLogxK

U2 - 10.1089/aid.2015.0086

DO - 10.1089/aid.2015.0086

M3 - Article

C2 - 26066390

AN - SCOPUS:84946709487

VL - 31

SP - 1089

EP - 1097

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 11

ER -